An interventional study of Probiotic supplements and Placebo supplements in Knee Osteoarthritis, sponsored by Lund University. Active, not recruiting at 1 site in Sweden. Open to female participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Lund University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Osteoarthritis, Knee with a site in Sweden — 12 open to participants now, 19 under way, none of them phase 3. Osteoarthritis, Knee · Sweden.
Among the 54 studies in Osteoarthritis, Knee with a site in Sweden, this one is the 28th largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 with no phase, reaches primary completion later than 10 of the 18 other live ones, and was the 46th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →12 of the 54 studies in Osteoarthritis, Knee with a site in Sweden are open now. Recruiting first, the newest first:
Vastra Gotaland Region · Sites in Sweden
Ages 30+
Vastra Gotaland Region · Sites in Sweden
Ages 18+
Uppsala University · Sites in Sweden
Ages 18–100
Region Skane · Sites in Sweden
Ages 25+
Danderyd Hospital · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 45 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 7
First in 2005; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 175 across the 38 interventional studies, 246 across the 16 observational. Of the 30 that completed or were terminated, 8 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 54 have an industry lead sponsor. The 10 most frequent:
Lund University is the lead sponsor of 234 studies on the registry; 36 are open to participants now.
Lund University has 8 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteoarthritis, Knee with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05584410Vastra Gotaland RegionDigitalization of Osteoarthritis Care | 2026-12-31 |
| NCT07212920Vastra Gotaland RegionValidity and Reliability of Video-Based Functional Physiotherapy Assessment of Subacute Knee Injuries | 2026-12-31 |
| NCT06459700Lund UniversityEffect of Probiotic Supplements on Osteoarthritis Outcomes | 2027-04-30 |
| NCT07875647Mälardalen UniversityPerson-Centred Digital Rehabilitation for Knee Osteoarthritis | 2027-09 |
| NCT07383740Vastra Gotaland RegionTest-Retest Reliability of a Submaximal Exercise Test in Patients With Hip and Knee Osteoarthritis | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 54 studies in Osteoarthritis, Knee with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dysbiosis of the gut microbiota is believed to contribute to the development and progression of osteoarthritis (OA), suggesting a role for probiotics in the treatment of OA. Animal studies have shown that certain probiotic strains decrease the inflammatory responses, pain sensitization and OA progression. There are, however, few clinical studies in humans to support this. In this double-blinded randomized controlled trial we will investigate the effect of 6-months probiotic supplements compared to placebo on OA related outcomes in females with diagnosed knee OA.
Aim:
To investigate the effect of 6-months probiotic supplements compared to placebo on OA related outcomes in females with diagnosed knee OA.
Design: Double-blinded randomized placebo controlled trial
Study arms: One treatment arm will receive probiotic supplement in opaque white capsules and the other treatment arm will receive identical opaque placebo capsules. The placebo product will contain maize starch powder. Study participants will take one capsule daily for six months.
Statistical analysis Main outcome: The independent T-test will be used to evaluate group differences in change in KOOS-12 scores between baseline and 6-months follow-up, given that all assumptions for parametric tests are satisfied. If assumptions are not met or if there are differences in baseline characteristics due to imbalanced randomization the Mann-Whitney U-test or regression analysis will be used as appropriate.
Secondary and explorative outcomes: The independent T-test (continuous, normal distributed data), the Mann-Whitney U-test (ordinal, non-normally distributed data) and cross-tabulations with Chi2 test (nominal data) will be used to evaluate differences in secondary and explorative outcomes between the two groups.
Estimated enrollment: 86 participants. Based on the ability to detect a 10-point difference in KOOS-12 with 80% power and α 0.05, 70 participants (35 per arm) will be needed. With an approximate drop-out rate of 20% from baseline to follow-up, 86 participants will be recruited.
Investigators: Eva Ageberg, PT, PhD, Professor in physical therapy, Lund University, Sweden (Principal investigator), Anna Cronström, physical therapist, PhD, Lund University, Sweden and Jessica Neilands, PhD, Associate Professor, Science manager, Probi AB, Lund, Sweden.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One arm will receive probiotic supplement in opaque white capsules, 1 each day for six months
Dietary Supplement: Probiotic supplements
One arm will receive identical opaque placebo capsules containing maize starch powder (placebo), 1 each day for six months
Dietary Supplement: Placebo supplements
See arm/group description
See arm/group description
Knee injury and Osteoarthritis Outcome Score (KOOS)-12
Change in the KOOS-12 (total score) from baseline to 6 months in the probiotic group compared with the placebo group. The KOOS-12 is scored from 1-100 (worst-best) scale.
Time frame: 6 months
Knee injury and Osteoarthritis Outcome Score (separate subscale score)
Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in Scores on the separate subscales (pain, symptoms, activity of daily living, sport/recreation and knee-related quality of life) from the full KOOS questionnaire. The KOOS is scored from 1-100 (worst-best) scale.
Time frame: 3 to 6 months
Visual Analogue Scale (VAS)
Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in VAS scores (pain severity), assessed on an ordinal scale from 0 to 10 where 0 indicates no pain and 10 worst possible pain the last week
Time frame: 3 to 6 months
Work Productivity and Activity Impairment questionnaire (WPAI)
Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in WPAI. The WPAI questionnaire includes 6 questions regarding employee's absenteeism, reduced job performance, work productivity loss, and activity impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
Time frame: 3 to 6 months
Patient Acceptable Symptom State (PASS)
Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in PASS. The PASS involves a question regarding if the patient is satisfied with their current knee function with to response options (yes/no)
Time frame: 3 to 6 months
Pain-relieving medication intake
Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in pain-relieving medication intake. Here the patients reports the type and dosage of any medication
Time frame: 3 to 6 months
Wish for surgery
Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in wish for surgery. The patients are asked if they wish to undergo surgery due to their knee problems (yes/no).
Time frame: 3 to 6 months
40m fast paced walk test
Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in 40m fast paced walk test, assessed as time taken to walk 4x10 meter as fast as possible
Time frame: 6 months
30 seconds sit to stand test
Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in the 30 seconds sit to stand test, assessed by the number of repetitions of sitting to standing from a chair during a period of 30 second.
Time frame: 6 months
Stair climb test
Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in the stair climb test, assessed as time taken to ascend and descend a flight of 5 stairs.
Time frame: 6 months
3 minute walk test
Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in the 3 minute walk test, assessed as distance walked during 3 minutes on a treadmill.
Time frame: 6 months
Molecular biomarkers for cartilage degeneration and inflammation.
Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in molecular biomarkers for cartilage degeneration and inflammation.
Time frame: 6 months
Kinematics assessed with 3D motion analysis
Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in Kinematics (joint angles in degrees) during the functional tasks
Time frame: 6 months
Kinetics assessed with 3D motion analysis and force plates
Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in kinetics (joint moments (newton meter)) during the functional tasks.
Time frame: 6 months
Intestinal barrier integrity
Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up a molecular biomarker for intestinal barrier integrity (Zonulin)
Time frame: 6 months
Plan to share: Yes — Plan description: De-identified IPD for primary and secondary outcomes will be made available upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Statistical analysis plan will be published in a study protocol before completion of the analysis.
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 33 months after the start.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 33 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.